Odonate Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>OT</div>
ODT -- USA Stock  

USD 14.51  0.36  2.42%

Lets try to review the odds of Odonate Therapeutics to fully recover from the newest drop as its shares went up 20.49%. Odonate Therapeutics's current daily volatility is 7.6 percent, with a beta of -0.38 and an alpha of -0.84 over DOW. As many of us are excited about pharmaceutical products, it is fair to review Odonate Therapeutics. We will analyze why Odonate Therapeutics investors may still consider a stake in the business.
Published over three weeks ago
View all stories for Odonate Therapeutics | View All Stories
Should you buy Odonate Therapeutics after the newest volatility gain?
Odonate Therapeutics has roughly 125.42 M in cash with (102.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.9. Our trade recommendations tool can cross-verify current analyst consensus on Odonate Therapeutics and to analyze the firm potential to grow in the current economic cycle.
Investing in Odonate Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Odonate Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Odonate Therapeutics's Liquidity

Odonate Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Odonate Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Odonate Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Odonate Therapeutics's total debt and its cash.

How Odonate utilizes its cash?

To perform a cash flow analysis of Odonate Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Odonate Therapeutics is receiving and how much cash it distributes out in a given period. The Odonate Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Odonate Therapeutics Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Odonate Therapeutics reported Net Cash Flow from Operations of (96.64 Million) in 2019

Odonate Therapeutics Correlation with Peers

Investors in Odonate can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Odonate Therapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Odonate Therapeutics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Odonate is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Odonate for more details

Breaking down Odonate Therapeutics Indicators

Odonate Therapeutics maintains Sharpe Ratio (i.e. Efficiency) of -0.0832, which implies the firm had -0.0832% of return per unit of risk over the last month. Macroaxis standpoint towards forecasting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Odonate Therapeutics exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to check Odonate Therapeutics risk adjusted performance of (0.17), and Coefficient Of Variation of (791.95) to confirm the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will Odonate Therapeutics newest gain continue?

Risk Adjusted Performance just dropped to -0.17, may call for upcoming price depreciation. Odonate Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Odonate Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Odonate Therapeutics volatility.

Our Conclusion on Odonate Therapeutics

Whereas few other entities in the biotechnology industry are either recovering or due for a correction, Odonate may not be as strong as the others in terms of longer-term growth potentials. To summarize, as of the 29th of August 2020, our analysis shows that Odonate Therapeutics almost neglects market trends. The firm is undervalued and projects close to average probability of distress for the next 2 years. However, our overall 30 days buy-hold-sell advice on the firm is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Odonate Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com